Do analysts recommend SBTX or AVLN?

Avalyn Pharma has a consensus target price of $59.00, suggesting a potential upside of 110.19%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Avalyn Pharma is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Avalyn Pharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.20

Which has better valuation & earnings, SBTX or AVLN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A Avalyn Pharma N/A N/A N/A N/A N/A

Is SBTX or AVLN more profitable?

Avalyn Pharma's return on equity of 0.00% beat Silverback Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silverback Therapeutics N/A -29.62% -28.20% Avalyn Pharma N/A N/A N/A

Which has preferable earnings & valuation, AVTE or SBTX?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A

Is AVTE or SBTX more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aerovate Therapeutics N/A -90.19% -77.47% Silverback Therapeutics N/A -29.62% -28.20%

Which has preferable valuation and earnings, SBTX or ELYM?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A

Is SBTX or ELYM more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Eliem Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silverback Therapeutics N/A -29.62% -28.20% Eliem Therapeutics N/A -47.03% -45.97%

Do analysts prefer SBTX or LWAC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 LightWave Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, SBTX or LWAC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A LightWave Acquisition N/A N/A N/A N/A N/A

Is SBTX or LWAC more profitable?

LightWave Acquisition's return on equity of 0.00% beat Silverback Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silverback Therapeutics N/A -29.62% -28.20% LightWave Acquisition N/A N/A N/A

Silverback Therapeutics (SBTX) Competitors

$9.81 +0.05 (+0.51%)

As of 06/15/2026

Compare

SBTX vs. AVLN, CALT, AVTE, ELYM, and LWAC

Should you buy Silverback Therapeutics stock or one of its competitors? MarketBeat compares Silverback Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Silverback Therapeutics include Avalyn Pharma (AVLN), Calliditas Therapeutics AB (publ) (CALT), Aerovate Therapeutics (AVTE), Eliem Therapeutics (ELYM), and LightWave Acquisition (LWAC).

How does Silverback Therapeutics compare to Avalyn Pharma?

Silverback Therapeutics (NASDAQ:SBTX) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

74.9% of Silverback Therapeutics shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A

Avalyn Pharma has a consensus target price of $59.00, suggesting a potential upside of 110.19%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Avalyn Pharma is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20

Avalyn Pharma's return on equity of 0.00% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Avalyn Pharma	N/A	N/A	N/A

In the previous week, Avalyn Pharma's average media sentiment score of 0.43 beat Silverback Therapeutics' score of 0.00 indicating that Avalyn Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Avalyn Pharma	Neutral

Summary

Avalyn Pharma beats Silverback Therapeutics on 7 of the 9 factors compared between the two stocks.

How does Silverback Therapeutics compare to Calliditas Therapeutics AB (publ)?

Silverback Therapeutics (NASDAQ:SBTX) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

In the previous week, Silverback Therapeutics' average media sentiment score of 0.00 equaled Calliditas Therapeutics AB (publ)'saverage media sentiment score.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Calliditas Therapeutics AB (publ)	Neutral

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Silverback Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Silverback Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Silverback Therapeutics' return on equity of -29.62% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Silverback Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

Summary

Silverback Therapeutics and Calliditas Therapeutics AB (publ) tied by winning 5 of the 10 factors compared between the two stocks.

How does Silverback Therapeutics compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Aerovate Therapeutics' average media sentiment score of 0.00 equaled Silverback Therapeutics'average media sentiment score.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
Silverback Therapeutics	Neutral

74.9% of Silverback Therapeutics shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

Silverback Therapeutics' return on equity of -29.62% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Silverback Therapeutics	N/A	-29.62%	-28.20%

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

Summary

Silverback Therapeutics beats Aerovate Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Silverback Therapeutics compare to Eliem Therapeutics?

Silverback Therapeutics (NASDAQ:SBTX) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

In the previous week, Silverback Therapeutics' average media sentiment score of 0.00 equaled Eliem Therapeutics'average media sentiment score.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Eliem Therapeutics	Neutral

74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Silverback Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the broader market.

Silverback Therapeutics' return on equity of -29.62% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Eliem Therapeutics	N/A	-47.03%	-45.97%

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Summary

Silverback Therapeutics beats Eliem Therapeutics on 6 of the 8 factors compared between the two stocks.

How does Silverback Therapeutics compare to LightWave Acquisition?

Silverback Therapeutics (NASDAQ:SBTX) and LightWave Acquisition (NASDAQ:LWAC) are both small-cap pharmaceutical preparations industry companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

LightWave Acquisition's return on equity of 0.00% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
LightWave Acquisition	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A

In the previous week, LightWave Acquisition's average media sentiment score of 1.87 beat Silverback Therapeutics' score of 0.00 indicating that LightWave Acquisition is being referred to more favorably in the news media.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
LightWave Acquisition	Very Positive

Summary

LightWave Acquisition beats Silverback Therapeutics on 4 of the 6 factors compared between the two stocks.

Get Silverback Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SBTX vs. The Competition

Export

Metric	Silverback Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$211.66M	$930.53M	$6.45B	$12.20B
Dividend Yield	N/A	4.84%	2.66%	5.66%
P/E Ratio	-4.05	1.43	23.92	24.34
Price / Sales	N/A	128.71	517.49	135.40
Price / Cash	N/A	20.06	27.48	37.92
Price / Book	1.32	7.92	10.50	6.70
Net Income	-$89.48M	-$4.88M	$3.56B	$337.21M
7 Day Performance	14.60%	2.09%	0.18%	1.78%
1 Month Performance	32.12%	1.63%	1.53%	3.64%
1 Year Performance	-36.26%	45.53%	24.25%	28.19%

Silverback Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SBTX Silverback Therapeutics	N/A	$9.81 +0.5%	N/A	-36.6%	$211.66M	N/A	N/A	83	High Trading Volume
AVLN Avalyn Pharma	4.851 of 5 stars	$28.78 +0.9%	$59.00 +105.0%	N/A	$1.28B	N/A	N/A	51	Short Interest Increase
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
AVTE Aerovate Therapeutics	N/A	$15.26 +0.3%	N/A	+126.9%	$442.31M	N/A	N/A	20	Gap Up High Trading Volume
ELYM Eliem Therapeutics	N/A	$11.14 +3.4%	N/A	+807.9%	$331.29M	N/A	N/A	9	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SBTX) was last updated on 6/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silverback Therapeutics (SBTX) Competitors

SBTX vs. AVLN, CALT, AVTE, ELYM, and LWAC

How does Silverback Therapeutics compare to Avalyn Pharma?

Summary

How does Silverback Therapeutics compare to Calliditas Therapeutics AB (publ)?

Summary

How does Silverback Therapeutics compare to Aerovate Therapeutics?

Summary

How does Silverback Therapeutics compare to Eliem Therapeutics?

Summary

How does Silverback Therapeutics compare to LightWave Acquisition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBTX vs. The Competition

Silverback Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silverback Therapeutics (SBTX) Competitors

SBTX vs. AVLN, CALT, AVTE, ELYM, and LWAC

How does Silverback Therapeutics compare to Avalyn Pharma?

Do insiders & institutionals hold more shares of SBTX or AVLN?

Which has better valuation & earnings, SBTX or AVLN?

Do analysts recommend SBTX or AVLN?

Is SBTX or AVLN more profitable?

Does the media favor SBTX or AVLN?

Summary

How does Silverback Therapeutics compare to Calliditas Therapeutics AB (publ)?

Does the media refer more to SBTX or CALT?

Which has better valuation and earnings, SBTX or CALT?

Do insiders & institutionals hold more shares of SBTX or CALT?

Is SBTX or CALT more profitable?

Which has more risk & volatility, SBTX or CALT?

Summary

How does Silverback Therapeutics compare to Aerovate Therapeutics?

Does the media favor AVTE or SBTX?

Do institutionals & insiders believe in AVTE or SBTX?

Which has more risk and volatility, AVTE or SBTX?

Is AVTE or SBTX more profitable?

Which has preferable earnings & valuation, AVTE or SBTX?

Summary

How does Silverback Therapeutics compare to Eliem Therapeutics?

Does the media prefer SBTX or ELYM?

Do insiders and institutionals have more ownership in SBTX or ELYM?

Which has more risk & volatility, SBTX or ELYM?

Is SBTX or ELYM more profitable?

Which has preferable valuation and earnings, SBTX or ELYM?

Summary

How does Silverback Therapeutics compare to LightWave Acquisition?

Is SBTX or LWAC more profitable?

Do analysts prefer SBTX or LWAC?

Do institutionals and insiders believe in SBTX or LWAC?

Which has better valuation & earnings, SBTX or LWAC?

Does the media refer more to SBTX or LWAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBTX vs. The Competition

Silverback Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools